Interferon alfa-2a therapy for life-threatening hemangiomas of infancy - PubMed (original) (raw)
Clinical Trial
. 1992 May 28;326(22):1456-63.
doi: 10.1056/NEJM199205283262203.
Affiliations
- PMID: 1489383
- DOI: 10.1056/NEJM199205283262203
Free article
Clinical Trial
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
R A Ezekowitz et al. N Engl J Med. 1992.
Free article
Erratum in
- N Engl J Med 1994 Jan 27;330(4):300
- Additional corrections: interferon for hemangiomas of infancy.
Ezekowitz A, Mulliken J, Folkman J. Ezekowitz A, et al. N Engl J Med. 1995 Aug 31;333(9):595-6. doi: 10.1056/NEJM199508313330913. N Engl J Med. 1995. PMID: 7623913 No abstract available.
Abstract
Background and methods: Most hemangiomas are small, harmless birthmarks that appear soon after birth, proliferate for 8 to 18 months, and then slowly regress over the next 5 to 8 years, leaving normal or slightly blemished skin. In rare cases, hemangiomas can endanger vital structures, with a mortality of up to 60 percent. About a third of these life-threatening hemangiomas respond to treatment with corticosteroids, but for the others there is no safe and effective treatment. We evaluated the effects of daily subcutaneous injections of interferon alfa-2a (up to 3 million units per square meter of body-surface area) in 20 neonates and infants with life-threatening or vision-threatening hemangiomas that failed to respond to corticosteroid therapy.
Results: In 18 of the 20 patients the hemangiomas regressed by 50 percent or more after an average of 7.8 months of treatment (range, 2 to 13). One infant died of refractory proliferation of a lesion and consumptive coagulopathy. The condition of three other patients who had large hemangiomas associated with consumptive coagulopathies that were unresponsive to conventional therapies stabilized after seven days of treatment with interferon alfa-2a alone. Transient side effects of treatment with interferon alfa-2a included fever, neutropenia (one patient), and skin necrosis (one patient). No long-term toxicity has been observed after a mean follow-up of 16 months.
Conclusions: Interferon alfa-2a appears to induce the early regression of life-threatening corticosteroid-resistant hemangiomas of infancy.
Comment in
- Interferons--expanding therapeutic roles.
Borden EC. Borden EC. N Engl J Med. 1992 May 28;326(22):1491-3. doi: 10.1056/NEJM199205283262209. N Engl J Med. 1992. PMID: 1374161 No abstract available. - Caution in regard to treatment of hemangiomas with interferon alfa-2a.
Vora AJ, Lilleyman JS. Vora AJ, et al. N Engl J Med. 1992 Oct 29;327(18):1321-2. doi: 10.1056/NEJM199210293271819. N Engl J Med. 1992. PMID: 1489461 No abstract available.
Similar articles
- [Interferon for hemangiomas of infancy].
Segal N, Barak Y. Segal N, et al. Harefuah. 1994 Apr 15;126(8):438-40, 491-2. Harefuah. 1994. PMID: 8070722 Hebrew. - Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas.
Tamayo L, Ortiz DM, Orozco-Covarrubias L, Durán-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R. Tamayo L, et al. Arch Dermatol. 1997 Dec;133(12):1567-71. Arch Dermatol. 1997. PMID: 9420543 Review. - The use of interferon alfa-2a for life-threatening hemangiomas.
MacArthur CJ, Senders CW, Katz J. MacArthur CJ, et al. Arch Otolaryngol Head Neck Surg. 1995 Jun;121(6):690-3. doi: 10.1001/archotol.1995.01890060088018. Arch Otolaryngol Head Neck Surg. 1995. PMID: 7772325 Clinical Trial. - [Severe hemangiomas treated with interferon alpha-2b: seven cases].
Léauté-Labrèze C, Labbé L, Grenier N, Berge J, Vergnes P, Taïeb A. Léauté-Labrèze C, et al. Ann Dermatol Venereol. 1998 Mar;125(3):174-8. Ann Dermatol Venereol. 1998. PMID: 9747242 French. - Treatment of hemangiomatosis with recombinant interferon alfa.
White CW. White CW. Semin Hematol. 1990 Jul;27(3 Suppl 4):15-22. Semin Hematol. 1990. PMID: 2197730 Review.
Cited by
- Treatment of hemangiomas in children using a Nd:YAG laser in conjunction with ice cooling of the epidermis: techniques and results.
Vlachakis I, Gardikis S, Michailoudi E, Charissis G. Vlachakis I, et al. BMC Pediatr. 2003 Apr 12;3:2. doi: 10.1186/1471-2431-3-2. Epub 2003 Apr 12. BMC Pediatr. 2003. PMID: 12697072 Free PMC article. - Classification and imaging of vascular malformations in children.
Abernethy LJ. Abernethy LJ. Eur Radiol. 2003 Nov;13(11):2483-97. doi: 10.1007/s00330-002-1773-8. Epub 2002 Dec 12. Eur Radiol. 2003. PMID: 14564473 Review. - Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.
Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, Davis DW, Fidler IJ. Ozawa S, et al. Neoplasia. 2001 Mar-Apr;3(2):154-64. doi: 10.1038/sj.neo.7900128. Neoplasia. 2001. PMID: 11420751 Free PMC article. - Antiangiogenesis as a novel therapeutic concept in pediatric oncology.
Schweigerer L. Schweigerer L. J Mol Med (Berl). 1995 Oct;73(10):497-508. doi: 10.1007/BF00198901. J Mol Med (Berl). 1995. PMID: 8581511 Review. No abstract available. - Extremely Rare Case of Cavernous Haemangioma of Submandibular Gland.
Kalra R, Rizvi S, Pathak VK, Nayak P. Kalra R, et al. Iran J Otorhinolaryngol. 2022 Nov;34(125):319-326. doi: 10.22038/IJORL.2022.64705.3221. Iran J Otorhinolaryngol. 2022. PMID: 36474490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical